| scholarly article | Q13442814 |
| P2093 | author name string | Evelyne Decullier | |
| François Chapuis | |||
| An-Wen Chan | |||
| P2860 | cites work | Drug discovery in jeopardy | Q22306297 |
| Clinical trial registration: the differing views of industry, the WHO, and the Ottawa Group | Q24812113 | ||
| Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors | Q28305451 | ||
| Publication bias in clinical research | Q29541186 | ||
| Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles | Q29618882 | ||
| The existence of publication bias and risk factors for its occurrence | Q34373168 | ||
| Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors | Q34389549 | ||
| Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). | Q36104338 | ||
| Publication bias: evidence of delayed publication in a cohort study of clinical research projects | Q36246225 | ||
| Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards | Q36728722 | ||
| Presentation and subsequent publication rates of phase I oncology clinical trials | Q40395097 | ||
| Compulsory registration of clinical trials | Q42399567 | ||
| Further lessons from the TGN1412 tragedy | Q42422420 | ||
| After the London tragedy, is it still possible to consider Phase I is safe? | Q42758188 | ||
| Free access to medical information: a moral right? | Q43024727 | ||
| Role of a research ethics committee in follow-up and publication of results | Q51028089 | ||
| Clinical trial registration: a statement from the International Committee of Medical Journal Editors. | Q53284937 | ||
| Risks in new drug development: approval success rates for investigational drugs | Q73924789 | ||
| Adverse events in phase-I studies: a report in 1015 healthy volunteers | Q74562259 | ||
| Phase I clinical trials: a call for papers | Q80207284 | ||
| A personal perspective on the Royal Statistical Society report of the working party on statistical issues in first-in-man studies | Q80216340 | ||
| SuperMAB on trial | Q82968634 | ||
| Urgent changes needed for authorisation of phase I trials | Q83188199 | ||
| Clinical trial registration: transparency is the watchword | Q83817845 | ||
| Trial registers: protecting patients, advancing trust | Q83817848 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | e1000034 | |
| P577 | publication date | 2009-02-17 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | Inadequate dissemination of phase I trials: a retrospective cohort study | |
| P478 | volume | 6 |
| Q29303281 | A deviation from standard design? Clinical trials, research ethics committees, and the regulatory co-construction of organizational deviance |
| Q85036838 | Are results from pharmaceutical-company-sponsored studies available to the public? |
| Q36673516 | Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting |
| Q36367067 | Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency |
| Q38808792 | Characteristics and Dissemination of Phase 1 Trials Approved by a UK Regional Office in 2012. |
| Q35759905 | Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov |
| Q45951344 | Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database. |
| Q30435820 | Delta inflation: a bias in the design of randomized controlled trials in critical care medicine |
| Q35189592 | Disease specific productivity of american cancer hospitals |
| Q28555016 | Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials |
| Q38795557 | Nonpublication of trial results for new neurological drugs: A systematic review. |
| Q35844255 | Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study |
| Q36008577 | Patient enrollment and logistical problems top the list of difficulties in clinical research: a cross-sectional survey |
| Q33659105 | Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications. |
| Q36665273 | Risks of phase I research with healthy participants: A systematic review |
| Q46698001 | Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program |
| Q28607112 | Why clinical translation cannot succeed without failure |
Search more.